Having results in primates with its ricin toxin vaccine Rivax is "almost like you've got phase II data," Soligenix Inc.'s chief scientific officer Oreola Donini told BioWorld Today, which is probably why shares of the Princeton, N.J.-based company (NASDAQ:SNGX) skyrocketed 43.6 percent, or $1.12, to close Wednesday at $3.69. Read More
LONDON – Synpromics Ltd has raised £5.2 million (US$6.7 million) in a series B round to advance the development and commercialization of its synthetic promoter technology for controlling and directing gene expression. Read More
Ultragenyx Pharmaceutical Inc. said it believes data from a phase III study testing burosumab (KRN23), a recombinant fully human monoclonal IgG1 antibody, are sufficient to support a BLA filing this year in X-linked hypophosphatemia (XLH), a bone disease characterized by phosphate wasting due to excess activity of FGF23. Read More
LONDON – Pharma company CEOs have made public pledges to continue donating drugs for treating neglected tropical diseases (NTDs) until they are eliminated, at a World Health Organization (WHO) meeting held to review progress in tackling NTDs that affect one in six people around the world. Read More
The U.S. Senate Judiciary Committee is looking into claims that insurance companies are charging patients a so-called "brand penalty," in addition to their copay or coinsurance, when their doctor deems the brand drug is medically necessary even though generics are available. Read More
Verona Pharma plc, of London, which is focused on developing and commercializing therapeutics for the treatment of respiratory diseases, filed its F1-A with the SEC to offer 4.44 million American depositary shares (ADSs), with each ADS representing eight ordinary shares. Read More
Brainstorm Cell Therapeutics Inc., of Hackensack, N.J., reported that preclinical research on Nurown mesenchymal stem cells (MSC) as used in a mouse model of autism was published in the April 2017 edition of Behavioural Brain Research. Read More
Kancera AB, of Stockholm, plans to begin a phase I trial to evaluate for KAND-567, an orally available small molecule that blocks CX3CR1, the Fractalkine receptor. The agent was shown in preclinical models to combat relapses in autoimmune disease and nerve inflammation and pain associated with chemotherapy. Read More
